Intelligence · Clinical pipeline
Autoimmune & immunology R&D Pipeline
Autoimmune, rheumatology, and immunology biologics in clinical development.
Quick answer
Autoimmune & immunology: NovaPharmaNews indexes 985 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.
Top sponsors
- Takeda 87 programs
- Chinese Academy of 58 programs
- Anaxis Pharma 52 programs
- Janssen-Cilag International N.V 34 programs
- Novartis India 32 programs
- First People's Hospital 23 programs
- Lakefront Biotherapeutics NV 22 programs
- AbbVie 21 programs
- AbbVie Deutschland GmbH 20 programs
- Regeneron UK 20 programs
- HOFFMANN-LA ROCHE 19 programs
- Pacira Ireland 18 programs
Pipeline programs
-
-, Rozanolixizumab
Lacuna Pharma Pty Ltd
Generalized Myasthenia Gravis
1 trial -
-, Rozanolixizumab
Lacuna Pharma Pty Ltd
Generalized Myasthenia Gravis
1 trial -
01-13
Apimeds Pharmaceuticals US
Osteoarthritis of the Knee
1 trial -
1305-0046
Boehringer Ingelheim
Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)
1 trial -
20-01/BetaSal-S
Alphapharm Pty Ltd
Chronic stable plaque psoriasis
1 trial -
20190529
Amgen
Juvenile psoriatic arthritis
1 trial -
20190531
Amgen
Behçet’s disease is a chronic, relapsing, multisystem inflammatory disorder of unknown etiology characterized by 4 major symptoms (oral aphthous ulcers, genital ulcers, skin lesions, and ocular lesions) and occasionally by 5 minor symptoms (arthritis, gastrointestinal ulcers, epididymitis, vascular lesions, and central nervous system [CNS] symptoms) (Cho, 2012). Juvenile idiopathic arthritis is a heterogeneous group of chronic inflammatory disorders that initially presents in children by the age of 16 years. It refers to arthritis of at least 6 weeks duration of unknown etiology that begins in children less than 16 years old. Juvenile idiopathic arthritis has an annual incidence of 2 to 20 cases per 100 000 population and a prevalence of 16 to 150 cases per 100 000 population. It is an autoimmune disorder marked by abnormalities of immune responses (Adelowo, 2010).
1 trial -
230LE301
Biogen
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
1 trial -
230LE303
Biogen
systemic lupus erythematosus
1 trial -
230LE304
Biogen
systemic lupus erythematosus
1 trial -
230LE306
Biogen
Systemic lupus erythematosus
1 trial -
25 mg Ontamalimab
Takeda
Crohn's Disease
1 trial -
410701BS
Lacuna Pharma Pty Ltd
Plaque psoriasis
1 trial -
608
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Axial Spondyloarthritis, Non-Radiographic
1 trial -
608 Q2W
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Plaque Psoriasis Patients
1 trial -
608 Q2W
Sunshine Guojian Pharmaceutical (Shanghai) Co.,
Psoriasis
1 trial -
750 mg Imsidolimab
Vanda Pharmaceuticals Netherlands B.V.
Generalized Pustular Psoriasis
1 trial -
77242113CRD3001
Janssen-Cilag International N.V.
Moderately to Severely Active Crohn's Disease
1 trial -
77242113PSA3001
Janssen-Cilag International N.V.
Active Psoriatic Arthritis
1 trial -
77242113PSO3001
Janssen-Cilag International N.V.
Moderate to Severe Plaque Psoriasis
1 trial -
77242113PSO3002
Janssen-Cilag International N.V.
Moderate to Severe Plaque Psoriasis
1 trial -
77242113PSO3003
Janssen-Cilag International N.V.
Plaque Psoriasis
1 trial -
77242113PSO3004
Janssen-Cilag International N.V.
Moderate to Severe Plaque Psoriasis
1 trial -
77242113PSO3006
Janssen-Cilag International N.V.
Moderate to Severe Plaque Psoriasis
1 trial -
80202135SLE3001
Janssen-Cilag International N.V.
Systemic Lupus Erythematosus
1 trial -
A3921145
Pfizer Australia Pty Ltd
Juvenile Idiopathic Arthritis (JIA)
1 trial -
A3921210
Pfizer Australia Pty Ltd
Ulcerative Colitis (UC)
1 trial -
AB-01-004
Dr Reddy''s Laboratories (Australia) Pty Ltd
Rheumatoid Arthritis
1 trial -
AIN457 150 mg
Novartis Pharmaceuticals
Moderate to Severe Chronic Plaque-Type Psoriasis
1 trial -
ALXN1720 Placebo Product, Gefurulimab
Alexion Europe SAS
Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)
1 trial -
AMZ001 Diclofenac gel
Amzell
Osteoarthritis of Knee
1 trial -
APHP200038
Pari Pharma GmbH
lupus nephritis
1 trial -
APHP230823
Pari Pharma GmbH
Adults aged at least 18 years with painful base-of-thumb osteoarthritis
1 trial -
APHP240792
Pari Pharma GmbH
Septic arthritis
1 trial -
APHP240804
Pari Pharma GmbH
Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.
1 trial -
APHP240920
Pari Pharma GmbH
Cutaneous lupus erythematosus
1 trial -
ARGX-113-2008
argenx
Generalized Myasthenia Gravis
1 trial -
ARGX-113-2308
argenx
Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
1 trial -
ARGX-113-2315
argenx
Ocular Myasthenia Gravis
1 trial -
ARQ-151 0.3% cream
Arcutis Biotherapeutics
Chronic Plaque Psoriasis
1 trial -
AXS-02
Axsome Therapeutics
Osteoarthritis, Knee
1 trial -
Adalimumab
AbbVie
Juvenile Psoriatic Arthritis
1 trial -
Adalimumab
AbbVie
Psoriatic Arthritis
1 trial -
Afimkibart
Hoffmann-La Roche
Moderately to Severely Active Crohns Disease
1 trial -
Alicaforsen
IONIS PHARMACEUTICALS INC
Crohn's Disease
2 trials -
Amchafibrin
Lxo Ireland Designated Activity Company
Osteoarthritis, Knee
1 trial -
Amifampridine Phosphate
CATALYST PHARMACEUTICALS, INC.
Myasthenia Gravis, Generalized
1 trial -
Amifampridine Phosphate
CATALYST PHARMACEUTICALS, INC.
Myasthenia Gravis, MuSK
1 trial
Frequently asked questions
How many autoimmune & immunology pipeline programs are tracked?
985 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.